drugset
drugset / Trial / NCT04213170

Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer

NCT04213170 ↗

Phase 2 Unknown 60 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective phase II clinical study to assess the efficacy of Sintilimab combined with Bevacizumab for driving gene-negative, asymptomatic brain metastases from non-small cell lung cancer by intracranial ORR(iORR),also iPFS,ORR and PFS.The safety and tolerability is evaluated as well.

Timeline

Start
2019-04-29
Primary completion
2022-12
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 15 mg/kg —
Subject Sintilimab Monoclonal antibody 200 mg —

Indications

metastatic malignant neoplasm in the brain non-small cell lung carcinoma